Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Thursday, September 30, 2021.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q3 FY2021 (2021-09-30): -433.63%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
-193.02%
RETURN ON EQUITY (ROE) AVG 3Y
-61.34%
RETURN ON EQUITY (ROE) AVG 5Y
-74.84%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
PTC Therapeutics, Inc.
Market Cap
$5.32B
Return on Equity (ROE)
N/A
TTM Avg
-193.02%
3Y Avg
-61.34%
5Y Avg
-74.84%
Market Cap
$5.20B
Return on Equity (ROE)
24.56%
TTM Avg
11.91%
3Y Avg
-7.82%
5Y Avg
-3.31%
Market Cap
$5.21B
Return on Equity (ROE)
-25.83%
TTM Avg
-24.61%
3Y Avg
-23.01%
5Y Avg
-16.21%
Market Cap
$5.20B
Return on Equity (ROE)
-177.24%
TTM Avg
-283.26%
3Y Avg
-317.97%
5Y Avg
-235.28%
Market Cap
$5.20B
Return on Equity (ROE)
18.24%
TTM Avg
20.62%
3Y Avg
17.32%
5Y Avg
27.02%
Market Cap
$5.19B
Return on Equity (ROE)
-70.85%
TTM Avg
-75.76%
3Y Avg
-70.25%
5Y Avg
-57.77%
Market Cap
$5.52B
Return on Equity (ROE)
-9.09%
TTM Avg
-8.34%
3Y Avg
-4.98%
5Y Avg
-4.98%
Market Cap
$5.07B
Return on Equity (ROE)
8.67%
TTM Avg
8.42%
3Y Avg
7.80%
5Y Avg
5.80%
Market Cap
$5.07B
Return on Equity (ROE)
-161.00%
TTM Avg
-110.38%
3Y Avg
-86.51%
5Y Avg
-75.97%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| PTC Therapeutics, Inc. (PTCT) | $5.32B | N/A | -193.02% | -61.34% | -74.84% |
| Sotera Health Company (SHC)vs › | $5.20B | 24.56% | 11.91% | -7.82% | -3.31% |
| CRISPR Therapeutics AG (CRSP)vs › | $5.21B | -25.83% | -24.61% | -23.01% | -16.21% |
| Travere Therapeutics, Inc. (TVTX)vs › | $5.20B | -177.24% | -283.26% | -317.97% | -235.28% |
| Doximity, Inc. (DOCS)vs › | $5.20B | 18.24% | 20.62% | 17.32% | 27.02% |
| Cogent Biosciences, Inc. (COGT)vs › | $5.19B | -70.85% | -75.76% | -70.25% | -57.77% |
| MiniMed Group, Inc. Common Stock (MMED)vs › | $5.52B | -9.09% | -8.34% | -4.98% | -4.98% |
| Merit Medical Systems, Inc. (MMSI)vs › | $5.07B | 8.67% | 8.42% | 7.80% | 5.80% |
| Scholar Rock Holding Corporation (SRRK)vs › | $5.07B | -161.00% | -110.38% | -86.51% | -75.97% |
| Waystar Holding Corp. (WAY)vs › | $5.06B | 3.38% | 1.14% | -0.67% | -0.98% |
ROE
N/A
ROA
-1.2%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2021-09-30 | -433.63% |
| 2021-06-30 | -198.93% |
| 2021-03-31 | -155.21% |
| 2020-12-31 | -90.91% |
| 2020-09-30 | -86.40% |
| 2020-06-30 | -75.42% |
| 2020-03-31 | -55.25% |
| 2019-12-31 | -42.33% |
| 2019-09-30 | -33.49% |
| 2019-06-30 | -43.63% |
| 2019-03-31 | -35.27% |
| 2018-12-31 | -36.52% |
| 2018-09-30 | -20.33% |
| 2018-06-30 | -22.91% |
| 2018-03-31 | -46.04% |
| 2017-12-31 | -50.50% |
| 2017-09-30 | -73.39% |
| 2017-06-30 | -63.92% |
| 2017-03-31 | -128.87% |
| 2016-12-31 | -118.84% |
| 2016-09-30 | -118.61% |
| 2016-06-30 | -105.25% |
| 2016-03-31 | -88.66% |
| 2015-12-31 | -57.11% |
| 2015-09-30 | -54.53% |
| 2015-06-30 | -52.63% |
| 2015-03-31 | -43.02% |
| 2014-12-31 | -31.41% |
| 2014-09-30 | -41.91% |
| 2014-06-30 | -27.49% |
| 2014-03-31 | -20.87% |
| 2013-12-31 | -37.77% |
| 2013-09-30 | -26.46% |
| 2013-06-30 | -28.01% |
| 2013-03-31 | -100.72% |
